Analysis of CD137l and IL-17 expression in tumor tissue as prognostic indicators for gliblastoma

International Journal of Biological Sciences

Volumn 9, Issue 2, 2013, Pages 134-141

  Cui, Xiangli ^a   Xu, Zhiqin ^b   Zhao, Zhigang ^a   Sui, Dali ^a   Ren, Xiaohui ^a   Huang, Qiming ^c   Qin, Jiazhen ^d   Hao, Limin ^c   Wang, Zhenguang ^c   Shen, Li ^e,f   Lin, Song ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c Beijing WDWK Biotech CoLtd   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^f PEKING UNIVERSITY   (China)

Author keywords

CD137l; Glioblastoma; Interleukin 17; Overall survival

Indexed keywords

BIOLOGICAL MARKER; CD137 LIGAND; INTERLEUKIN 17;

ARTICLE; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; OVERALL SURVIVAL.; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

CD137L; GLIOBLASTOMA; INTERLEUKIN-17; OVERALL SURVIVAL.;

4-1BB LIGAND; BIOLOGICAL MARKERS; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-17; KAPLAN-MEIER ESTIMATE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84873734527     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.4891     Document Type: Article

References (27)

1. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer.2010; 10(5):319-331.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005; 352 (10):987-996.
3. Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicatorin basal-like breast cancer. Breast Cancer Res. 2012; 14(2):R48.
4. Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, Lardon F, Vermorken JB. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol. 2010; 11:19.
5. DeBenedette MA, Shahinian A, Mak TW, et al. Costimulation of CD28- T lymphocytes by 4-1BB ligand. J Immunol. 1997; 158(2):551-559.
6. Cannons JL, Lau P, Ghumman B, et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol. 2001; 167(3):1313-1324.
7. Lynch DH. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev. 2008; 222:277-286.
8. Mou YG, Xie H T, Peng H, et al. Clinical significance of 4-1BBL protein expression in human glioma tissues. Chin J Pathophysiol. 2010; 26(12):2342-2346.
9. Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007; 25:821-852.
10. Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumour environments. Blood 2009; 114:1141-1149.
11. Anderson RC, Anderson DE, Elder JB, et al. Lack of B7 expression, nothuman leukocyte antigen expression, facilitates immune evasion by human malignant gliomas. Neurosurgery. 2007; 60(6):1129-1136.
12. Mu YG, Peng H, Zhang JY, et al. Expression of costimulator 4-1BBL and B7-1 on glioma cell lines. Ai Zheng. 2006; 25(3):326-329.
13. Fleming AJ, Chi SN. Brain tumors in children. Curr Probl Pediatr Adolesc Health Care. 2012; 42(4):80-103
14. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain. 2007; 130(Pt 10): 2596-2606.
15. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64(19):6892-6899.
16. Wilcox, R. A., K. Tamada, S. Strome, and L. Chen. Signaling through NK cell-associated CD137 promotes both helper function for CD8 cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J. Immunol. 2002;169:4230-4236.
17. Wilcox, R. A., K. Tamada, D. B. Flies, G. Zhu, A. I. Chapoval, B. R. Blazar, W. M. Kast, and L. Chen. Ligation of CD137 receptor prevents and reversesestablished anergy of CD8 cytolytic T lymphocytes in vivo. Blood.2004;103: 177-184.
18. Kim, Y-J, Kim, S H, Mantel, P, et al. Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses. Eur J Immunol. 1998; 28(3): 881-890.
19. Zhang Q, Liu S, Ge D, et al. Interleukin-17 Promotes Formation and Growth of Prostate Adenocarcinoma in Mouse Models. Cancer Res. 2012; 72(10):2589-2599.
20. Kuang DM, Peng C, Zhao Q, et al. Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. J Immunol. 2010; 185(3):1544-1549.
21. Gu FM, Gao Q, Shi GM, et al. Intratumoral IL-17(+) Cells and Neutrophils show Strong Prognostic Significance in Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2012; [Epub ahead of print]
22. Hamaï A, Pignon P, Raimbaud I, et al. Human TH17 Immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivo. Cancer Res. 2012; 72(5):1059-1063.
23. Sharma RK, Schabowsky RH, Srivastava AK, et al. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Res. 2010; 70(10):3945-3954.
24. Wu C, Guo H, Wang Y, Gao Y, Zhu Z, Du Z. Extracellular domain of human 4-1BBL enhanced the function of cytotoxic T-lymphocyte induced by dendritic cell. Cell Immunol. 2011; 271(1):118-123.
25. Wainwright DA, Sengupta S, Han Y, et al. The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS One. 2010; 5(10):e15390.
26. Hu J, Mao Y, Li M, Lu Y. The profile of Th17 subset in glioma. Int Immunopharmacol. 2011; 11(9):1173-1179.
27. Wang Q, Zhang P, Zhang Q, et al. Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J. 2008; 49(2):192-200.